
Merck Sees Pipeline Diversification Opportunity in $1.3B EyeBio Acquisition
Merck is acquiring the clinical-stage startup EyeBio for $1.3 billion in cash upfront, with potential milestone payments of up to $1.7 billion. EyeBio develops drugs for retinal conditions, with their lead program Restoret targeting the Wnt pathway in the eye to restore and maintain the blood-retinal barrier in diabetic macular edema. Early clinical data for…